06/20/2012 - The House easily approved legislation on Wednesday that would reauthorize the Food and Drug Administration's user-fee program for brand-name drugs and medical devices, and expand that program to cover biosimilars and generic drugs.

After a brief debate in which both parties praised their rare and cordial bipartisan effort, members approved S. 3187, the FDA Safety and Innovation Act, in a voice vote.

"S. 3187 is a reflection of the hard work put in by both members and staff, and of everyone's willingness to put partisanship aside," House Energy and Commerce Committee Chairman Fred Upton (R-Mich.) said on the House floor.

***

Read the full blog post, House Cheers, Approves FDA Reform Bill, on The Hill's website.